Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | PCSK9 | Q8NBP7 | 3/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | CETP | P11597 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12690242 | 0.86 | HCAR3 (0.44) | ALDH1A1KDM4ESMN1; SMN2HCAR3HCAR2 | |
| SCHEMBL15382054 | 0.77 | SMN1; SMN2 (0.59) | ALDH1A1KDM4ESMN1; SMN2HCAR3HCAR2 | |
| SCHEMBL15382066 | 0.77 | SMN1; SMN2 (0.59) | ALDH1A1KDM4ESMN1; SMN2HCAR3HCAR2 | |
| SCHEMBL12690245 | 0.77 | HCAR3 (0.40) | ALDH1A1KDM4ESMN1; SMN2HCAR3LMNA | |
| SCHEMBL12693765 | 0.75 | ALDH1A1 (0.56) | ALDH1A1KDM4ESMN1; SMN2HCAR3HCAR2 | |
| SCHEMBL17082526 | 0.75 | ALDH1A1 (0.56) | ALDH1A1KDM4ESMN1; SMN2HCAR3HCAR2 | |
| SCHEMBL19203405 | 0.74 | KDM4E (0.41) | ALDH1A1KDM4ESMN1; SMN2HCAR3HCAR2 | |
| SCHEMBL19203407 | 0.74 | KDM4E (0.41) | ALDH1A1KDM4ESMN1; SMN2HCAR3HCAR2 | |
| SCHEMBL30658431 | 0.74 | KDM4E (0.41) | ALDH1A1KDM4ESMN1; SMN2HCAR3HCAR2 | |
| SCHEMBL17353647 | 0.74 | ALDH1A1 (1.00) | ALDH1A1KDM4ESMN1; SMN2PCSK9MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580825-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20120245162-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245162-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | ALDH1A1 641/4885KDM4E 3731/4885SMN1; SMN2 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.